Author:
Goebell Peter J.,Groshen Susan L.,Schmitz-Dräger Bernd J.
Publisher
Springer Science and Business Media LLC
Reference84 articles.
1. Malkin A (1992) Tumor markers. In: Tannock IF, Hill RP (eds) The basic science of oncology, 2nd edn. McGraw-Hill, New York
2. Gudjónsson S, Isfoss BL, Hansson K, Domanski AM, Warenholt J, Soller W, Lundberg LM, Liedberg F, Grabe M, Månsson W (2007) The value of the urovysion((R)) Assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol [Epub ahead of print]
3. Birkhahn M, Mitra AP, Cote RJ (2007) Molecular markers for bladder cancer: the road to a multimarker approach. Expert Rev Anticancer Ther 7:1717–1727
4. Herrmann E, Eltze E, Bierer S, Köpke T, Görge T, Neumann J, Hertle L, Wülfing C (2007) VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival. Anticancer Res 27:3127–3133
5. Tsai YS, Tzai TS, Chow NH (2007) Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol Int 79:210–216
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献